<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259346</url>
  </required_header>
  <id_info>
    <org_study_id>17151</org_study_id>
    <secondary_id>I1F-MC-RHCU</secondary_id>
    <nct_id>NCT04259346</nct_id>
  </id_info>
  <brief_title>A Study of Two Formulations of Ixekizumab in Healthy Participants</brief_title>
  <official_title>Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different formulations of ixekizumab. One&#xD;
      formulation (Reference) is approved by the Food and Drug Administration (FDA) and one&#xD;
      formulation (Test) is not approved. This study will compare how much of each formulation gets&#xD;
      into the blood stream. Information about any side effects that may occur will also be&#xD;
      collected. The study will last up to about four months for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Actual">February 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: Cmax of ixekizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of Ixekizumab</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: AUC of ixekizumab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ixekizumab (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approved formulation of ixekizumab administered as a subcutaneous (SC) injection via autoinjector (AI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ixekizumab (Test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test formulation of ixekizumab administered as a SC injection via AI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixekizumab</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Ixekizumab (Reference)</arm_group_label>
    <arm_group_label>Ixekizumab (Test)</arm_group_label>
    <other_name>LY2439821</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are healthy male or female participants who agree not to become pregnant or are male&#xD;
             or female participants with chronic stable medical problems, that in the&#xD;
             investigator's opinion will not place the subject at increased risk by participating&#xD;
             in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a significant history of, or current, cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of&#xD;
             the investigator poses an unacceptable risk to the participant if participating in the&#xD;
             study&#xD;
&#xD;
          -  Are allergic or hypersensitive to the study medicine&#xD;
&#xD;
          -  Had a vaccination with a live vaccine within 12 months prior to the first check-in or&#xD;
             intend to get a vaccine for tuberculosis within 12 months of completing treatment on&#xD;
             this study&#xD;
&#xD;
          -  Have any type of hepatitis, human immunodeficiency virus (HIV) infection, or other&#xD;
             serious infection&#xD;
&#xD;
          -  Show evidence of active or latent tuberculosis (TB)&#xD;
&#xD;
          -  Presence of significant neuropsychiatric disorder or a recent history of depression&#xD;
&#xD;
          -  Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion&#xD;
             of the investigator, would pose an unacceptable risk to the participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1, 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixekizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

